Structural requirements of alloxan and ninhydrin for glucokinase inhibition and of glucose for protection against inhibition
Open Access
- 1 November 1988
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 95 (3) , 851-859
- https://doi.org/10.1111/j.1476-5381.1988.tb11714.x
Abstract
1 In order to elucidate the mechanism underlying the interactions between glucose and alloxan when competing for the sugar binding site of glucokinase from pancreatic B-cells or liver, the structural requirements of the enzyme for inhibition by alloxan and for protection by glucose were determined. 2 With a half-maximal inhibitory concentration of 5 μm, alloxan was the most potent pyrimidine derivative inhibitor of glucokinase. Uramil was a less potent enzyme inhibitor. A variety of other pyrimidine derivatives and related substances were ineffective. 3 Ninhydrin also inhibited glucokinase with a half-maximal inhibitory concentration of 5 μm. Isatin was a slightly less potent enzyme inhibitor. Several other indoline derivatives were ineffective. 4 Only glucose derivatives with a sufficiently bulky substituent in position C-2, such as the glucokinase substrates glucose and mannose and the inhibitors mannoheptulose, glucosamine, and N-acetylglucosamine, protected glucokinase against inhibition by alloxan by binding to the active site of the enzyme. Glucose epimers which differed in other positions did not protect the enzyme against alloxan inhibition. 5 DTT (dithiothreitol) protected glucokinase against inhibition by alloxan and reversed the inhibition of the enzyme induced by alloxan. Thus the mechanism of glucokinase inhibition by alloxan and other inhibitors, such as uramil and ninhydrin, is an oxidation of functionally essential SH groups of the enzyme, where the most reactive keto group of the inhibitor acts as the hydrogen acceptor. The protective action of glucose and several C-2 epimers demonstrates that these functionally essential SH groups are situated in the sugar binding site of the glucokinase. 6 The present results support our contention, that the pancreatic B-cell glucokinase is the major target mediating the inhibition of insulin secretion by alloxan.This publication has 31 references indexed in Scilit:
- Identification of glucokinase as an alloxan-sensitive glucose sensor of the pancreatic beta-cellDiabetes, 1986
- Inhibition of rat liver glucokinase by alloxan and ninhydrin.CHEMICAL & PHARMACEUTICAL BULLETIN, 1985
- A refined model of the sugar binding site of yeast hexokinase BJournal of Molecular Biology, 1978
- Sequencing a protein by X-ray crystallographyJournal of Molecular Biology, 1978
- Ninhydrin inhibition of glucose-induced insulin releaseDiabetologia, 1977
- The preparation of, and studies on, free cell suspensions from mouse pancreatic isletsDiabetologia, 1974
- Preparation and Properties of New Derivatives of AlloxanJournal of the American Chemical Society, 1949
- Diabetogenic Action of Alloxan DerivativesNature, 1945
- Das Alloxan als Oxydationsmittel für Thiolgruppen, als Kapillargift und als KrampfgiftNaunyn-Schmiedebergs Archiv für experimentelle Pathologie und Pharmakologie, 1930
- Untersuchungen über die Natur der HarnsäureEuropean Journal of Organic Chemistry, 1838